|
The MEVPRO clinical trial program is an investigational prostate cancer treatment option for patients with metastatic prostate cancer. These clinical trials provide patients with the study medicine, Mevrometostat, which is taken as tablets twice per day with enzalutamide.
How does Mevrometostat work? The study medicine targets the EZH2 protein known for controlling cell growth. In some people, the EZH2 gene may become abnormal or make too much of the proteins, which can cause prostate cancer cells to grow and the cancer to progress. By blocking the abnormal EZH2 activity in cells, the study medicine may help prevent or delay hormone therapy resistance and cancer progression.
This could be an important development and make a difference in outcomes for men with prostate cancer that become resistant to hormone therapy. These clinical trials are meant to help patients diagnosed with metastatic castrate-resistant prostate cancer (mCRPC). mCRPC is an advanced form of prostate cancer that no longer responds to hormone therapy. Read More Here to See if You're Eligible to Participate
|